Abstract
Aldose reductase enzyme (ALR2) of the polyol metabolic pathway, apart from its role as detoxifying enzyme towards toxic aldehydes, osmoregulator in the kidney and regulator of sperm maturation, was first found to be implicated in the etiology of the long term diabetic complications. However, to date, emerging reports have suggested that under normal glucose concentration, ALR2 may be up-regulated by factors other than hyperglycemia and therefore be involved also in other pathological processes that have become major threats to human health in the 21st century. Such pathologies are a number of cardiac disorders, inflammation, mood disorders, renal insufficiency and ovarian abnormalities. In addition, ALR2 was found to be over-expressed in different human cancers such as liver, breast, ovarian, cervical and rectal cancers. Although several aldose reductase inhibitors (ARIs) have progressed to the clinical level, only one is currently on the market. Thus, attention is currently targeted to discover ARIs of distinct chemical structures, being neither hydantoin nor carboxylic acid derivatives. The present review focuses on the molecular mechanisms by which ALR2 is implicated in a number of pathologies, on various aspects concerning its catalytic mechanism and its active site, and on the main classes of ARIs that have been developed to date, as well as on reported (quantitive) structure-activity relationships. The presented data aim to support the notion that ARIs are of pharmacotherapeutic interest for the pharmaceutical community and highlight essential aspects for the development of efficient and potent ARIs.
Keywords: Aldose reductase enzyme and aldose reductase inhibitors, long-term diabetic complications, cardiovascular disorders, inflammation, mood disorders, renal insufficiency, ovarian abnormalities, cancer
Current Medicinal Chemistry
Title: Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Volume: 16 Issue: 6
Author(s): Polyxeni Alexiou, Kyriaki Pegklidou, Maria Chatzopoulou, Ioannis Nicolaou and Vassilis J. Demopoulos
Affiliation:
Keywords: Aldose reductase enzyme and aldose reductase inhibitors, long-term diabetic complications, cardiovascular disorders, inflammation, mood disorders, renal insufficiency, ovarian abnormalities, cancer
Abstract: Aldose reductase enzyme (ALR2) of the polyol metabolic pathway, apart from its role as detoxifying enzyme towards toxic aldehydes, osmoregulator in the kidney and regulator of sperm maturation, was first found to be implicated in the etiology of the long term diabetic complications. However, to date, emerging reports have suggested that under normal glucose concentration, ALR2 may be up-regulated by factors other than hyperglycemia and therefore be involved also in other pathological processes that have become major threats to human health in the 21st century. Such pathologies are a number of cardiac disorders, inflammation, mood disorders, renal insufficiency and ovarian abnormalities. In addition, ALR2 was found to be over-expressed in different human cancers such as liver, breast, ovarian, cervical and rectal cancers. Although several aldose reductase inhibitors (ARIs) have progressed to the clinical level, only one is currently on the market. Thus, attention is currently targeted to discover ARIs of distinct chemical structures, being neither hydantoin nor carboxylic acid derivatives. The present review focuses on the molecular mechanisms by which ALR2 is implicated in a number of pathologies, on various aspects concerning its catalytic mechanism and its active site, and on the main classes of ARIs that have been developed to date, as well as on reported (quantitive) structure-activity relationships. The presented data aim to support the notion that ARIs are of pharmacotherapeutic interest for the pharmaceutical community and highlight essential aspects for the development of efficient and potent ARIs.
Export Options
About this article
Cite this article as:
Alexiou Polyxeni, Pegklidou Kyriaki, Chatzopoulou Maria, Nicolaou Ioannis and Demopoulos J. Vassilis, Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century, Current Medicinal Chemistry 2009; 16 (6) . https://dx.doi.org/10.2174/092986709787458362
DOI https://dx.doi.org/10.2174/092986709787458362 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Cholinotrophic Molecular Substrates of Mild Cognitive Impairment in the Elderly
Current Alzheimer Research In the Rush for Green Gold: Can Green Tea Delay Age-Progressive Brain Neurodegeneration?
Recent Patents on CNS Drug Discovery (Discontinued) The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics
Current Medicinal Chemistry Molecular Action of Metformin in Hepatocytes: An Updated Insight
Current Diabetes Reviews NF-κB Inhibition Resolves Cognitive Deficits in Experimental Type 2 Diabetes Mellitus through CREB and Glutamate/GABA Neurotransmitters Pathway
Current Neurovascular Research Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Current Drug Targets Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Current Drug Discovery Technologies Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Prevalence and Associates of Foot Deformities among Patients with Diabetes in Jordan
Current Diabetes Reviews Vascular Effects of Insulin and Their Relation to Endothelial Dysfunction, Insulin Resistance and Hypertension
Current Hypertension Reviews Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design Connexins, Diabetes and the Metabolic Syndrome
Current Protein & Peptide Science C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Patient, System and Clinician Level Interventions to Address Disparities in Diabetes Care
Current Diabetes Reviews Antioxidant Enzyme Mimics with Synergism
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinsons Disease
Mini-Reviews in Medicinal Chemistry MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Advanced Glycation and Advanced Lipoxidation: Possible Role in Initiation and Progression of Diabetic Retinopathy
Current Pharmaceutical Design Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry